ARTICLE | Product Development
Amphista degrades a cancer target using a non-traditional ligase
Amphista’s targeted glues combine the advantages of PROTACs and molecular glues to create selective, orally bioavailable therapies
May 23, 2024 11:18 AM UTC
Amphista has revealed data showing it can degrade a cancer target using a “targeted glue” that recruits a non-traditional E3 ligase, with superior bioavailability compared with cereblon-based degraders.
Molecular glues have historically been found serendipitously, meaning the MOA is discovered after showing efficacy. ...